Poor
Not Aligned
Patient Risk:
Low
Summary
The claims relate to FDA orphan drug designation timing/recognition, which is not addressed in the provided prescribing-information excerpts. Therefore, the response cannot be verified against the supplied label text.
Category Scores
Accurate Statements
Unsupported Statements
The FDA orphan drug designation date for nusinersen is November 21, 2012.
The provided SPINRAZA prescribing information excerpts (Sections 1, 2, 5, 6, 12, 14) do not contain orphan drug designation dates, so this cannot be supported by the supplied label text.
Nusinersen was granted FDA orphan drug designation for spinal muscular atrophy (SMA).
The provided prescribing information excerpts do not discuss orphan drug designation or the orphan designation indication, so this cannot be supported by the supplied label text.
The designation entry (including the date and indication) can be confirmed in FDA’s orphan drug database listing for nusinersen.
The provided prescribing information excerpts do not mention the FDA orphan drug database or confirmation of designation entries; this cannot be supported by the supplied label text.
Contradictions
Important Omissions
Any label-based information supporting orphan drug designation date/indication (or reference to the orphan drug database) for nusinersen/SPINRAZA.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The challenged claims concern administrative orphan-drug designation details rather than dosing, contraindications, warnings, or patient-specific safety guidance; no direct label-governed safety content is contradicted by these statements based on the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Orphan drug designation date/indication claims are not present or supported in the provided FDA-approved prescribing information excerpts, so alignment cannot be established.
Suggested Improvement
Restrict claims to information contained in the provided prescribing information sections (e.g., indications, dosing/administration, warnings/precautions, adverse reactions). If orphan designation details are needed, cite the relevant non-label source or provide label excerpts that include orphan drug designation information.